Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.
You may also be interested in...
Genzyme Reports More Good News For Mozobil
Second Phase III trial shows twice the stem cell mobilization power called for in multiple myeloma protocol, adding to high efficacy shown in lymphoma study reported in July.
Genzyme Reports More Good News For Mozobil
Second Phase III trial shows twice the stem cell mobilization power called for in multiple myeloma protocol, adding to high efficacy shown in lymphoma study reported in July.
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.